Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

• Status: Terminated
• Trial end date: 2014-01-02
• Target enrollment: 0
• Participant gender: All

Summary

The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Ranolazine

Criteria

Inclusion Criteria:

• History of stable coronary artery disease

Exclusion Criteria:

• Inability or unwillingness to participate in multiple exercise treadmill tests and/or any other requirements of this study as assessed by the Investigator.

• History of chronic atrial fibrillation.

Other protocol-defined inclusion/exclusion criteria may apply.